26 May 2022
Diaceutics PLC
("Diaceutics" or "the Company")
Results of Annual General Meeting
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, is pleased to announce that all resolutions proposed at its Annual General Meeting held earlier today, were duly passed by a show of hands.
The proxy votes received from shareholders in respect of each resolution are set out below and are available on the Company's website, www.diaceutics.com.
|
Resolution
|
For (excluding at Chair's discretion)
|
Against
|
Total votes cast
|
Withheld
|
|
|
|
Number of votes
|
%
|
Number of votes
|
%
|
|
Number of votes
|
|
1
|
Ordinary resolution to receive and consider the 2021 Financial Statements
|
62,700,675
|
100.00%
|
0
|
0.00%
|
62,700,675
|
Nil
|
|
2
|
Ordinary resolution to approve the directors' remuneration report
|
62,693,325
|
99.99%
|
7,350
|
0.01%
|
62,700,675
|
Nil
|
|
3
|
Ordinary resolution to re-elect Nick Roberts as a director
|
62,700,675
|
100.00%
|
0
|
0.00%
|
62,700,675
|
Nil
|
|
4
|
Ordinary resolution to re-elect Charles Hindson as a director
|
61,651,904
|
98.32%
|
900,000
|
1.44%
|
62,551,904
|
Nil
|
|
5
|
Ordinary resolution to re-appoint PricewaterhouseCoopers LLP as auditors
|
62,550,243
|
99.75%
|
1,661
|
0.01%
|
62,551,904
|
Nil
|
|
6
|
Ordinary resolution to authorise the directors to determine the remuneration of the auditors
|
62,700,675
|
100.00%
|
0
|
0.00%
|
62,700,675
|
Nil
|
|
7
|
Ordinary resolution to authorise the directors to allot shares
|
62,699,175
|
100.00%
|
0
|
0.00%
|
62,700,675
|
1,500
|
|
8
|
Special resolution to authorise the directors to disapply pre-emption rights
|
62,697,164
|
99.9%
|
2,011
|
0.01%
|
62,699,175
|
1,500
|
|
9
|
Special resolution to authorise the directors to purchase own shares
|
60,606,084
|
99.99%
|
8,661
|
0.01%
|
62,614,745
|
2,085,930
|
Enquiries:
|
Diaceutics PLC
|
|
|
Peter Keeling, Chief Executive Officer
|
Via Alma PR
|
|
Nick Roberts, Chief Financial Officer
|
|
|
|
|
|
Stifel Nicolaus Europe Limited (Nomad & Broker)
|
Tel: +44 (0)20 7710 7600
|
|
Ben Maddison, Stewart Wallace, Nick Adams
|
|
|
|
|
|
Alma PR
|
Tel: +44(0)20 3405 0205
|
|
Caroline Forde, Kieran Breheny, Matthew Young
|
[email protected]
|
About Diaceutics
At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.
DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.